Lonza’s Synaffix entered a licensing agreement with Qurient Therapeutics to develop a dual-payload antibody-drug conjugate (ADC) leveraging Synaffix’s clinical-stage GlycoConnect®, HydraSpace®, and exatecan-based linker-payload technologies. The ADC will combine two cytotoxic agents with distinct mechanisms to target refractory solid tumors, enhancing therapeutic efficacy and overcoming payload resistance. Qurient will spearhead development and commercialization with access to Lonza's site-specific conjugation platform, marking a strategic advance in precision oncology therapeutics.